A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...

The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a ...

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Discover ADM's new solutions platform for GLP-1 consumers. With over 25 market-ready concepts, it assists those on ...

Brands like Kourtney Kardashian’s Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might ...